Wen, Y., Zhou, S., Xu, Y., Zhang, C., Feng, Z., Song, Y., . . . Pan, M. Donafenib versus sorafenib in triple therapy for unresectable hepatocellular carcinoma: A propensity score-matched multicenter analysis. BMC.
Chicago Style (17th ed.) CitationWen, Yaohong, et al. Donafenib Versus Sorafenib in Triple Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score-matched Multicenter Analysis. BMC.
MLA (9th ed.) CitationWen, Yaohong, et al. Donafenib Versus Sorafenib in Triple Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score-matched Multicenter Analysis. BMC.
Warning: These citations may not always be 100% accurate.